ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

ClinicalTrials.gov ID: NCT05593614

Public ClinicalTrials.gov record NCT05593614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of ATX01 (Topical Amitriptyline Hydrochloride 10% and 15% w/w) in Comparison to Placebo, in Cancer Survivor Adult Patients With Chemotherapy-induced Peripheral Neuropathy (CIPN)

Study identification

NCT ID
NCT05593614
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
AlgoTherapeutix
Industry
Enrollment
276 participants

Conditions and interventions

Interventions

  • ATX01 10% Drug
  • ATX01 15% Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 27, 2023
Primary completion
Aug 31, 2024
Completion
Aug 31, 2024
Last update posted
Jul 15, 2024

2023 – 2024

United States locations

U.S. sites
8
U.S. states
5
U.S. cities
8
Facility City State ZIP Site status
South Lake Pain Institute Clermont Florida 34711
MGM Medical Care Research & Rehab, LLC Miami Florida 33173
Medsol Clinical Research Center, Inc Port Charlotte Florida 33952
Knight Neurology - Clinical Research Rockledge Florida 32955
Neuroscience Research Center, LLC. Overland Park Kansas 66210
The Center for Cancer and Blood Disorders (CCBD) Bethesda Maryland 20817
University of Rochester Medical Center Rochester New York 14642
HD Research Bellaire Texas 77401

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05593614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 15, 2024 · Synced Apr 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05593614 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →